VECAMYL® (mecamylamine HCI) is indicated for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension.
For assistance, call:
1-877-794-0008
A Comprehensive Team Including Pharmacists and Dedicated Care Coordinators.
VECAMYL Total Care Program staff will:
A Fully Integrated Specialty Pharmacy and Patient Services Program.
Dedicated staff are available to support patients one-on-one. The program offers a single point of contact for all of their needs related to securing an uninterrupted supply of VECAMYL.
Personalized Resources, a Phone Call Away.
Contact the VECAMYL Total Care Program at 1-877-794-0008 to begin the process of obtaining VECAMYL today.
Team members are available to assist Monday through Friday, 9am to 5pm ET.
VECAMYL® (mecamylamine HCI tablets USP) 2.5 mg is indicated for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension.
VECAMYL® should not be used in patients with mild, moderate, labile hypertension and may prove unsuitable in uncooperative patients. It should also not be given to patients with coronary insufficiency or recent myocardial infarction.
VECAMYL is contraindicated for patients with uremia and should be used with caution in patients with renal insufficiency revealed by elevated BUN.
In general, patients receiving antibiotics and sulfonamides should not be treated with VECAMYL.
VECAMYL is also contraindicated for patients with glaucoma, organic pyloric stenosis, or hypersensitivity to mecamylamine hydrochloride.
Tremor, choreiform movements, mental aberrations, and convulsions may occur rarely due to the ability of mecamylamine to readily penetrate into the brain and consequently cause central nervous system effects. These effects have occurred most often following large doses of VECAMYL, particularly in patients with cerebral or renal insufficiency.
When discontinuing VECAMYL, the drug should be withdrawn gradually and other antihypertensive therapy usually must be substituted. Sudden discontinuation of VECAMYL can cause hypertension to abruptly return, which in certain patients, for example those with malignant hypertension, may cause fatal cerebral events or acute congestive heart failure. The effects of VECAMYL may last for hours to days after stopping therapy.
Prior to prescribing VECAMYL, a patient's condition should be evaluated, particularly with respect to renal and cardiovascular function. Additional impairment resulting from hypotension in patients deficient in renal, cerebral, or coronary blood flow must be avoided. VECAMYL should be used with caution in patients with marked cerebral and coronary arteriosclerosis or who have had a recent cerebral vascular accident.
The action of VECAMYL may be potentiated by excessive heat, fever, infection, hemorrhage, pregnancy, anesthesia, surgery, vigorous exercise, other antihypertensive drugs, alcohol, and salt depletion due to diminished salt intake or increased salt excretion as a result of diarrhea, vomiting, excessive sweating, or diuretics.
Patients with prostatic hypertrophy, bladder neck obstruction, or urethral stricture should be treated with caution since urinary retention may occur with VECAMYL.
VECAMYL should immediately be discontinued and remedial steps taken if a patient has signs of paralytic ileus, such as frequent loose bowel movements with abdominal distention and decreased borborygmi.
Patients receiving antibiotics and sulfonamides generally should not be treated with VECAMYL.
The action of VECAMYL may be potentiated by anesthesia, other antihypertensive drugs, and alcohol.
VECAMYL is a potent, oral antihypertension agent and ganglion blocker.
Please See Full Prescribing Information